Cell Response Ltd Information

Over 90% of cancer patient mortality is due to drug resistance and most clinical trials fail due to drug resistance. Our proprietary synthetic lethality screening platform, Resistome™, rapidly identifies drug-specific resistance mechanisms and evaluates drug combinations which overcome drug-specific resistance to extend life for patients, as well as identifying refined biomarker strategies to improve the stratification of patients for treatment.